

ASP Health Named 'Top Pathology Solutions Provider 2025' by MedTech Outlook Magazine

Company blends human insight with cutting-edge technology to ensure faster and more accurate diagnoses and peace of mind for patients

NORTHBROOK, IL, UNITED STATES, September 10, 2025 /EINPresswire.com/ -- [ASP Health Inc.](https://www.asphhealth.com), a private medical device company committed to improving cancer survival rates by pioneering a new era of point-of-care pathology, has received the “Top Pathology Solutions Provider 2025” award from MedTech Outlook magazine. Its cover story notes that ASP Health’s pathology suite comprises a triad of innovative platforms — ASP Prep™, ASP View™ and ASP Assist™ — that bring speed, precision, and standardization to the point-of-care setting. “Our platforms drive a wave of transformation in diagnostic processes, enabling precise, real-time evaluations,” said Hari Subramanian, PhD, MBA, ASP Health’s chief operating officer.

ASP Health is developing cutting-edge tools that are accessible to all healthcare facilities by decentralizing diagnostics. In the MedTech Outlook article, ASP Health President and CEO John Hart said, “Our specialty is a complete end-to-end solution for preparing and viewing cell slides, enhanced by software that quickly identifies target cells to expedite the diagnostic decision-making process.”

“

Our platforms drive a wave of transformation in diagnostic processes, enabling precise, real-time evaluations”

Hari Subramanian, PhD, MBA

The company’s initial focus was to address the limitations commonly associated with the cancer diagnostic procedure known as Rapid On-Site Evaluation (ROSE). Recognizing the untapped power of automation in streamlining ROSE from a niche, manual process into a scalable, life-saving standard, ASP Health made ROSE the first use-case of its disruptive technology. In a testimonial

highlighted in the MedTech Outlook article, Gautam Balakrishnan, MD, interventional



Award from MedTech Outlook

pulmonologist, Mosaic Life Care, St. Joseph, MO, stated, "ASP Health helped us solve a common problem faced by many community hospitals — the inability to perform ROSE. The ROSE Prep™ system allows us to automatically prepare high-quality specimen slides and transmit real-time feedback with telepathology."

The cover story also highlighted how the company is "moving cancer diagnostics from bench to bedside." Users can tap into the advantages of ROSE View™ for timely diagnostic evaluations after seamless and successful specimen preparation using ROSE Prep™. The state-of-the-art, fully robotic ROSE View™ microscope is easy to operate and can be accessed remotely via the internet, allowing cytopathologists to assess samples from virtually anywhere. It's fast, reliable and clinically proven, accelerating timely decision-making.

With advances in artificial intelligence proliferating in the healthcare industry, ASP Health seamlessly integrated AI-based software into its remote microscope for smooth, fast, and confident clinical decisions. In the magazine profile, Dr. Subramanian explained, "AI-powered assistance acts as an extra set of eyes, ensuring no critical details are missed and significantly reducing the time required for diagnosis."

To download a copy of the MedTech Outlook article and for corporate information, visit asp-health.com.

To learn more about ASP Health's trailblazing platforms, healthcare providers, patients, and caregivers should visit EnhancingCancerDX.com.

Hariharan Subramanian
ASP Health
+1 425-241-7385
[email us here](#)



MedTech article page

This press release can be viewed online at: <https://www.einpresswire.com/article/847380563>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

